Explore Our Blog: Expert Articles and Updates​

In recent years, there has been a resurgence of interest in psychedelics as potential treatments for mental health disorders. Among the many substances being studied, N,N-Dimethyltryptamine (DMT) stands out due to its unique properties and rapid, intense effects. While traditionally associated with shamanic rituals and ayahuasca ceremonies, DMT is now being explored for its potential to alleviate anxiety. Could this powerful psychedelic be the key to unlocking relief for those struggling with anxiety disorders?

Welcome to Part 2 of our exploration into anxiety. Last year, we discussed common behaviors and symptoms associated with Social Anxiety Disorder in our blog: If You Can Relate, You May Have Social Anxiety Disorder. Today, we delve deeper, offering new insights and the latest information to help you understand this pervasive condition. If you find yourself relating to these experiences, it may be time to consider professional avenues, including potential participation in a clinical trial for anxiety.

Miami Lakes, FL – Segal Trials, a leading clinical research organization specializing in acute schizophrenia trials, has been recognized by the PPD Select Global Partnership Program for outstanding enrollment performance. This accolade was awarded for the site’s exemplary participation in the Phase 2 study of CVL-231 (Emraclidine), aimed at treating patients experiencing an acute exacerbation of psychosis.

[North Miami, FL – [August 21, 2024] – Segal Trials is proud to announce the completion of the first injection procedure in the DigniFI Study. The Women’s Health Team, under the leadership of Principal Investigator Steven Chavoustie, M.D., FACOG and Sub-Investigator Brittany Berre MSN, ARNP, FNP-C, worked diligently to prepare for this vital women's health study. The study's first injection procedure was performed on August 19, 2024.. Segal Trials also completed the first muscle tissue procurement procedure for the study on March 21, 2024.

The FDA's recent decision to pause the approval of MDMA-assisted therapy for PTSD is a reminder of the complexities in advancing groundbreaking treatments. While the...

Postpartum depression (PPD) continues to be a significant challenge affecting many new mothers, altering the joyous occasion of childbirth into a time of struggle and emotional turmoil. With advances in medical research, new treatment avenues are opening up, offering hope where traditional methods might fall short. One such promising field is the use of psychedelics in treating mood disorders like PPD.

In the wake of the COVID-19 pandemic, humanity has been ushered into what many might call a "new normal," a period marked by profound shifts in our way of life and, notably, in our collective mental health. The psychological aftermath of the pandemic, compounded by other life-altering events, has spotlighted an undeniable crisis: a dramatic surge in mental health issues, burdening an already overwhelmed and antiquated mental health treatment system. Traditional treatments for conditions like addiction, anxiety, depression, and PTSD have remained largely unchanged for decades, sparking a crucial conversation about the need for innovation in mental health care.

The resurgence of interest in psychedelics, once sidelined by regulatory crackdowns and societal skepticism, marks a pivotal turn in the quest for effective mental health treatments. Psychedelic drugs, encompassing substances like psilocybin (found in magic mushrooms), LSD, MDMA (ecstasy), and ayahuasca, have moved from the fringes of scientific inquiry to the forefront of innovative psychiatric research. This article delves into how psychedelics are revolutionizing the treatment of mental illnesses such as anxiety, depression, addiction, and PTSD, the limitations of current pharmaceutical options, and the promising horizon of psychedelic-assisted therapy, underscored by rigorous clinical research aiming for FDA approval.

Clinical trials have always been at the forefront of medical advancements. These carefully designed studies provide evidence for interventions, treatments, and diagnostic tests that form the foundation of modern medicine. As technology continues to evolve, clinical trials are also undergoing rapid transformations, giving rise to innovative methodologies and tools. Here, we delve into the future of clinical trials, focusing on the emerging trends that are redefining this critical field.

Postpartum depression (PPD) is a complex mood disorder that affects many new mothers in the weeks and months following childbirth. It’s essential to understand that PPD is more than just "baby blues," a term used to describe the mild, short-term sadness many women feel after giving birth. The symptoms of PPD can range from persistent feelings of sadness, hopelessness, and worthlessness to overwhelming fatigue, severe anxiety, and even thoughts of harming oneself or the baby. Some of the contributing factors include hormonal changes after childbirth, a history of depression or anxiety, childbirth-related trauma, and various stressors associated with new motherhood.